Voss Capital’s Cognition Therapeutics CGTX Stock Holding History

Voss Capital’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Sell	175,000 -25,000	-13%	-$29.6K	0.01%	59
2026 Q1	$152K	Sell	200,000 -79,340	-28%	-$92.4K	0.01%	51
2025 Q4	$377K	Sell	279,340 -20,660	-7%	-$33.5K	0.02%	52
2025 Q3	$405K	Sell	300,000 -150,000	-33%	-$205K	0.02%	53
2025 Q2	$139K	Hold	450,000	–	–	0.01%	54
2025 Q1	$189K	Sell	450,000 -50,000	-10%	-$29.4K	0.01%	54
2024 Q4	$351K	Buy	+500,000	New	+$247K	0.03%	43
2023 Q4	–	Sell	-60,222	Closed	-$86.7K	–	43
2023 Q3	$86.7K	Hold	60,222	–	–	0.01%	41
2023 Q2	$110K	Sell	60,222 -99,751	-62%	-$211K	0.01%	45
2023 Q1	$317K	Sell	159,973 -6,930	-4%	-$13.2K	0.04%	38
2022 Q4	$350K	Sell	166,903 -52,197	-24%	-$105K	0.07%	40
2022 Q3	$416K	Sell	219,100 -90,372	-29%	-$188K	0.12%	37
2022 Q2	$653K	Buy	309,472 +283,033	+1,071%	+$731K	0.21%	31
2022 Q1	$71K	Hold	26,439	–	–	0.02%	38
2021 Q4	$167K	Buy	+26,439	New	+$258K	0.05%	37

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Voss Capital's CGTX Position: Q2 2026 in Review

Voss Capital reduced its Cognition Therapeutics (CGTX) stake by 13% in Q2 2026, selling an estimated $29.6K and leaving 175,000 shares worth $201K. The position accounts for 0.01% of the portfolio, ranked #59.

Voss Capital first reported a position in CGTX in Q4 2021 and has held it in 15 quarters since. The position peaked at $653K in Q2 2022. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Voss Capital held 175,000 shares of Cognition Therapeutics worth $201K as of Q2 2026.
Voss Capital sold 25,000 Cognition Therapeutics shares in Q2 2026, an estimated $29.6K.
Cognition Therapeutics made up 0.01% of Voss Capital's portfolio in Q2 2026, its #59 holding.
Voss Capital first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 15 quarters since.
Voss Capital's Cognition Therapeutics position peaked at $653K in Q2 2022.
66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Voss Capital's 13F filing for Q2 2026, filed 14 Aug 2026.